P
ancreatic cancer is the fourth leading cause of death from cancer for both men and women in the United States. 1 Cigarette smoking, obesity, and family history of pancreatic cancer have been recognized as risk factors for pancreatic cancer. 2 The association of type 2 diabetes mellitus (DM2) and pancreatic cancer is complex. On one hand, DM2 can occur as a consequence of pancreatic cancer. 3, 4 On the other hand, there is accumulating evidence to strongly support a significant role of DM2 in pancreatic carcinogenesis. 5, 6 Insulin resistance, which is initially characterized by hyperglycemia and hyperinsulinemia, is a proposed mechanism underlying the association of DM2 or obesity with cancer. 7, 8 A growth-promoting hormone with mitogenic effects, insulin, could also up-regulate the bioavailability of insulin-like growth factor I by displacing it from binding proteins. 9 In addition, exocrine pancreatic tissue may be chronically exposed to local insulin concentrations much higher than the circulating insulin levels seen in hyperinsulinemic patients. 10 Although the association between DM2 and several types of human cancers is well established, few studies have investigated the role that antidiabetic therapies might have on this relationship. There are therapies for DM2 that increase the circulating insulin levels, for example, exogenous insulin or insulin analogues, insulin secretagogues (sulfonylureas and meglitinides), and treatments that reduce the insulin resistance (eg, biguanides and thiazolidinediones). 11 Two recent epidemiologic studies have found that diabetic patients treated with the biguanide metformin were less likely to develop cancer but that those treated with insulin or sulfonylurea were more likely to die of cancer. 12, 13 However, these studies did not specify the types of cancer affected. In experimental systems, metformin has been shown to have antioxidant and tumor growth inhibition activities. 14 -17 In a study using a hamster model, metformin had a significant protective effect against the development of pancreatic tumors induced by chemical carcinogens and a high-fat diet. 18 However, to our knowledge, no studies have been reported on the association of antidiabetic therapies and pancreatic cancer risk in humans. We therefore examined the association of antidiabetic therapies and pancreatic cancer risk in a large hospital-based case-control study.
Patients and Methods

Study Population
The study population consisted of patients from an ongoing hospital-based case-control study conducted at the University of Texas M. D. Anderson Cancer Center that began in 2004. The purpose of the ongoing study was to define environmental and genetic factors that contribute to the development of pancreatic cancer. The study was approved by the M. D. Anderson Cancer Center Institutional Review Board. The study design and patient population have previously been described in detail. 19 Cases were consecutively recruited from patients with newly diagnosed and pathologically confirmed pancreatic ductal adenocarcinoma who were seen at the M. D. Anderson Gastrointestinal Center. Controls were recruited from healthy individuals accompanying patients being treated at other centers in our institute. The controls were mostly spouses, and others were nonblood relatives and friends of patients with cancers other than gastrointestinal or smoking-related cancers; controls were not genetically related to the patients. Cases and controls were frequency matched by age (Ϯ5 years), sex, and race. All study subjects (both cases and controls) were US residents, had no prior history of cancer (except nonmelanoma skin cancer), and were able to communicate in English. Each study participant gave written informed consent to participate in a personal interview and to have a blood sample collected. As of May 2008, when the current analysis was conducted, a total of 1004 eligible cases and 867 controls were recruited and completed the interview. The recruitment rate (number of individuals recruited/number of individuals approached) was 81% for cases and 77% for controls. Thirty-one cases who were later not pathologically confirmed as having pancreatic adenocarcinoma and 4 controls who had incomplete questionnaire data were excluded from the analysis, leaving 973 cases and 863 controls in the current study.
Data Collection
Trained personnel administered a structured and validated questionnaire 20 to collect information on demographics and known or suspected risk factors for pancreatic adenocarcinoma (eg, cigarette smoking, alcohol consumption, family history of cancer, and medical history). The questionnaire was administered by personal interview, and no proxy interview was involved. Ever smokers were defined as individuals who had smoked more than 100 cigarettes in their lifetimes. Daily alcohol consumption (grams of ethanol per day) was calculated based on the type, duration, and frequency of alcoholic drinks reported. Family history of cancer was restricted to first-degree relatives. Mean body mass index (BMI) was calculated using the self-reported body weight at 30, 40, and 50 years of age and the selfreported usual height. According to the World Health Organization standard, BMIs of 18.5-24.9, 25-29.9, and Ͼ30 kg/m 2 were defined as normal body weight, overweight, and obesity, respectively. Diabetes was defined by the self-reported medical history. Diabetes in patients with cancer was also confirmed from their medical records. Diabetes-related information included age and year of diagnosis, whether used insulin and duration of use, and whether used oral antidiabetic medications, name of the medication, and duration of use. 
Measurement of Hemoglobin
Statistical Analysis
The distribution of categorical variables was compared between cases and controls by the Pearson 2 test. The association of pancreatic cancer with risk factors (eg, cigarette smoking, alcohol consumption, BMI, diabetes, and family history of cancer) was analyzed using multivariate unconditional logistic regression analysis. Age, sex, and race were included in all models.
Participants' duration of diabetes (time from diagnosis of diabetes to recruitment to the study) was categorized into one of 3 groups: Յ2, 3-5, or Ͼ5 years. Duration of diabetes was also dichotomized at 2 years to distinguish cases of DM2 from cases of diabetes caused by pancreatic cancer. Our rationale for setting the cutoff at 2 years is that pancreatic cancer progressing so rapidly that it is unlikely a case of pancreatic cancer-induced diabetes would go without cancer detection for more than 2 years.
Because the number of patients who received monotherapy was small, insulin use was not considered in the oral medication classification groups. Noninsulin antidiabetic medications were categorized into 4 groups: (1) insulin secretagogues (eg, sulfonylureas and meglitinides), (2) biguanides such as metformin, (3) thiazolidinediones (TZDs), and (4) other drugs, including ␣-glucosidase inhibitors, dipeptidyl peptidase-4, amylin analogues, and glucagon-like peptide 1 analogues. Because many patients used combination therapy, the drugs or combinations changed over time, and the number of patients in each monotherapy group was small, the final analysis used the categorical variables of ever or never use of insulin, insulin secretagogues, metformin, or TZDs. Duration of use for each type of therapy was categorized into one of 3 groups: Յ2, 3-5, or Ͼ5 years. The association of oral antidiabetic therapy and risk of pancreatic cancer was analyzed in multivariable logistic regression models including age, sex, race, smoking, alcohol, BMI, family history of cancer, duration of diabetes, and insulin use. To control for reversal causality due to pancreatic cancer-caused diabetes, risk of pancreatic cancer was esti-mated after exclusion of those with duration of diabetes Յ2 years. HbA 1c level (Յ7% or Ͼ7%), a marker of glycemic control, was compared between ever users and never users of each type of antidiabetic therapy by 2 test. The demographic and risk factors as well as duration of diabetes and insulin use were compared between metformin ever users and never users by 2 test. Fisher exact test was applied when any of the group had Ͻ5 subjects.
All statistical analyses were performed using SPSS version 15.0 (SPSS, Cary, NC) and Stata (Stata Corp, College Station, TX) software with 2-sided tests, with a P value of Ͻ.05 considered statistically significant.
Results
Characteristics of the Study Population
The characteristics of the study population, including risk factors for pancreatic cancer, are summarized in Table 1 . No significant differences in sex and education level were observed between cases and controls, but black subjects and individuals older than 70 years were underrepresented in the control group compared with the case group (P ϭ .007 and P ϭ .002, respectively).
Cigarette smoking, alcohol consumption, family history of cancer among first-degree relatives, and overweight or obesity were significantly associated with an increased risk of pancreatic cancer (Table 1) . Diabetes was associated with a 2.37-fold increased risk of pancreatic cancer (95% confidence interval [CI], 1.87-3.06). Diabetes was diagnosed at 18 years or younger only for 2 individuals, suggesting the vast majority of the diabetic patients in the study had DM2. Patients who were diagnosed with diabetes within 2 years of recruitment to the study had an odds ratio (OR) of 4.50 (95% CI, 2.96-6.84); those with a diabetes duration of 3-5 or Ͼ5 years had an OR of 1.71 (95% CI, 1.02-2.85; P ϭ .04) and 1.52 (95% CI, 1.05-2.21; P ϭ .028), respectively.
Association of Antidiabetic Therapy and Risk of Pancreatic Cancer
The frequencies with which each of the antidiabetic therapies were used are listed in Table 2 . Using nondiabetic Next we performed the analysis among subjects with diabetes only. Using never users as the referent group, ever users of insulin and ever users of insulin secretagogues had 4.99-and 2.52-fold increased risks of pancreatic cancer (P Ͻ .001 and P ϭ .005, respectively) ( Table 3 ). Ever users of metformin had a 62% reduction in the risk of pancreatic cancer (OR, 0.38; 95% CI, 0.22-0.69; P ϭ .001). Ever users of a TZD had a 55% higher risk of pancreatic cancer compared with never users, but the difference was not statistically significant (P ϭ .213). When the analysis was restricted to individuals who never used insulin, the risk association became stronger for insulin secretagogue ever users and weaker for metformin ever users. When individuals with duration of diabetes Յ2 years were excluded from the analysis, the association of insulin use or metformin use and risk of pancreatic cancer remained statistically significant ( Table 3 ).
The duration of antidiabetic therapy was evaluated for insulin, insulin secretagogue, and metformin use. Using never users as the referent group, short-term use (Յ2 years) of insulin, insulin secretagogues, or metformin was significantly associated with risk of pancreatic cancer. However, long-term use (Ͼ5 years) of metformin but not insulin or insulin secretagogues significantly modified the risk of pancreatic cancer (Table 4) . After exclusion of diabetes with duration of Յ2 years, the protective effect of metformin use against pancreatic cancer remained statistically significant, and use of insulin for Ͼ5 years also showed a significant effect on increased risk of pancreatic caner (P ϭ .049).
Glycemic Control and Other Potential Confounders
To demonstrate whether glycemic control was a confounding factor for the association between antidiabetic therapy and risk of pancreatic cancer, we measured HbA 1c level in 571 pancreatic cancer cases that were recruited after 2006. There was no significant difference in age (P ϭ .49), sex (P ϭ .62), race (P ϭ .11), smoking (P ϭ .75), history of diabetes (P ϭ .31), duration of diabetes (P ϭ .036), insulin use (P ϭ .54), and oral antidiabetic medication use (P ϭ .32) between patients with or without the HbA 1c test. A slightly higher frequency of obesity (11.4% vs 6.4%) was observed ). Ever users of insulin had a significantly higher frequency (58%) of poor glycemic control (HbA 1c Ͼ7%) than never users (28%; P Ͻ .001). No significant differences in HbA 1c levels were observed between ever users and never users of insulin secretagogues (P ϭ .87), metformin (P ϭ .54), or TZD (P ϭ .78).
We also examined the distribution of demographic and risk factors between ever and never users of metformin. As shown in Table 5 , among all the factors analyzed, insulin use was the only factor that showed a significant difference, that is, insulin was used among 47.6% of never users versus 25.7% of ever users of metformin (P Ͻ .001). To examine the potential confounding effect of cigarette smoking and obesity, 2 established risk factors for both pancreatic cancer and diabetes, we analyzed the association of metformin use and risk of pancreatic cancer by smoking and obesity status. The protective effect of metformin was slightly stronger in never smokers (OR, 0.37; 95% CI, 0.17-0.81) than that in ever smokers (OR, 0.44; 95% CI, 0.18-1.09), but the interaction of metformin and smoking was not significant (P interaction ϭ .56, likelihood ratio test). Similarly, the protective effect of metformin was statistically significant in individuals with normal body weight (BMI Ͻ25 kg/m 2 ) (OR, 0.35; 95% CI, 0.16-0.79; P ϭ .01) but was not significant in those with excess body weight (BMI Ͼ25 kg/m 2 ) (OR, 0.32; 95% CI, 0.02-5.36; P ϭ .42). The P value for interaction of metformin and BMI was .79.
Discussion
To our knowledge, the current case-control study is the first to show a statistically significant association between antidiabetic therapy and risk of pancreatic cancer. Our major observations are that diabetic subjects who ever used metformin, especially those with Ͼ5 years of use, had a reduced risk of pancreatic cancer compared with never users. In addition, there were some suggestive observations that diabetic patients who had used insulin or insulin secretagogues (sulfonylureas and meglitinides) had an increased risk of pancreatic cancer compared with never users. These observations are consistent with findings from 2 previous epidemiologic investigations 12, 13 and add evidence that antidiabetic therapy can affect the development of human cancer. Metformin, a biguanide, is an oral hypoglycemic agent commonly used for the treatment of DM2. The current study showed a robust protective effect of metformin against pancreatic cancer in diabetes. Although the number of patients with diabetes in this study was relatively small, the study has more than 80% power in detecting an OR of 0.3. Other diabetes-associated factors, such as the duration of diabetes, smoking, overweight or obesity, and glycemic control, did not have a significant confounding effect on the relationship between metformin use and risk of pancreatic cancer. Even though a higher frequency of insulin use was observed among never users of metformin compared with ever users, the protective effect of metformin remained statistically significant when the analysis was restricted to insulin never users.
Metformin reduces the level of glucose by decreasing hepatic glucose production, increasing glucose utilization and fatty acid oxidation. Like TZDs, but unlike insulin and insulin secretagogues, metformin decreases the plasma insulin level. 22 Metformin also has a modest weight-reducing effect, while the other classes of agents tend to cause weight gain. 23 Based on the current understanding, the direct molecular mechanism of action of metformin involves activation of the adenosine monophosphate activated protein kinase, which is a metabolite-sensing protein kinase family that is sensitive to increases in the adenosine monophosphate/adenosine triphosphate ratio. 24 Adenosine monophosphate activated protein kinase activation not only regulates many metabolic enzymes but also has been shown to inhibit the mTOR pathway, which may in turn regulate cell proliferation. 25 Furthermore, adenosine monophosphate activated protein kinase has recently been found to play a role in cell polarity and cell division. 26 Therefore, in addition to amelioration of hyperglycemia and hyperinsulinemia (factors that mediate the adverse impact of DM2 on cancer), metformin has direct effects on cancer cells to block the mitogenic effects of insulin and insulinlike growth factor I at postreceptor levels by blocking the phosphatidylinositol 3-kinase/Akt/mTOR signaling pathway and by inhibiting cell division. Indeed, cell culture experiments as well as animal model experiments have shown a direct antineoplastic effect of metformin. [27] [28] [29] Thus, the protective effect of metformin against pancreatic cancer observed in our study could be explained by the combination of all the effects of this drug discussed previously.
The association of insulin ever use and increased risk of pancreatic cancer was confounded by 2 factors: duration of diabetes and glycemic control. Among pancreatic cancer cases, many patients started to use insulin Յ2 years before their cancer diagnoses, perhaps because of worsening of diabetes caused by the cancer. Thus, the association between short-term insulin use and pancreatic cancer suggests reverse causality, that is, occult pancreatic cancer worsened diabetes within the 2 years before diagnosis of pancreatic cancer, causing the patients to initiate insulin therapy for glycemic control. On the other hand, we did observe a weak but significant association between long-term insulin use (Ͼ5 years) and increased risk of pancreatic cancer (OR, 2.78; 95% CI, 1.00 -7.73; P ϭ .049). However, the statistical power was limited because this observation was made in a very small number of study subjects (17 cases and 9 controls). The association between long-term insulin use and risk of pancreatic cancer needs to be further investigated in a larger study.
Insulin secretagogues as a monotherapy for DM2 showed the highest risk of pancreatic cancer in this study. However, because of the small number of insulin secretagogue ever users among controls, this observation could be by chance alone. Among diabetic subjects, the risk of pancreatic cancer was increased in short-term users but not long-term users of insulin secretagogues compared with never users, which does not support a role of this type of treatment on cancer. Because of the previous positive findings, the association between insulin secretagogue use and risk of pancreatic cancer should be investigated further in a larger study.
Our study has several potential limitations. As in any case-control study, recall bias is a concern. However, after cross-checking the diabetes history and information on current medications given by case subjects against their medical records, we found a high level of consistency. Moreover, a previous study indicated that 3% of survey respondents inaccurately reported their own prior histories of diabetes, which was the minimum misclassification rate among several medical conditions. 30 Our study was conducted in a single tertiary care referral hospital, so the data may not be generalizable to the general population. However, the prevalence of diabetes among controls in our study was quite comparable to previously reported frequencies in population-based case-control studies of pancreatic cancer. 31, 32 Even though our study has a large sample size, the statistical power is still limited when the analysis was restricted to diabetic subjects. Therefore, our observations need to be confirmed in large studies. Last, but not least, our study design could not show whether the reduced cancer risk is due to less severe diabetes that led to the choice of metformin or due to better-controlled diabetes by use of metformin. More detailed history on time and duration of each type of antidiabetic therapy use is required to address this question.
Because pancreatic cancer is a rapidly fatal but a relatively uncommon cancer, epidemiologic research on this disease is challenging. Our report seeks for replication efforts from other study populations to confirm or refute a possible role of antidiabetic therapy in pancreatic cancer. If the finding that metformin is protective against pancreatic cancer is confirmed, metformin may offer a tool for the primary prevention of pancreatic cancer among people with DM2. 11 
